| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J7-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J9-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-001 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_634f8d1e50258d2adef7e666d755b4f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6165d0a476ae27706bd6fa3e873812 |
| publicationDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016168553-A1 |
| titleOfInvention |
Deuterated obeticholic acid |
| abstract |
This invention relates to deuterated forms of obeticholic acid, and pharmaceutically acceptable salts thereof. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an agonist of the farnesoid X receptor (FXR). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022229302-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11472831-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106645497-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020030737-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021009332-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022152770-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019023103-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021144330-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111050772-A |
| priorityDate |
2015-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |